Clinician Letters

2022

    • CDC Updates COVID-19 Recommendations
    • COVID-19 Vaccine Update: Novavax and Bivalent Boosters
    • COVID-19 Therapeutic Update: Bebtelovimab is Available for Purchase Commercially
    • Monkeypox Clinical Evaluation and Management
    • JYNNEOS Vaccine for People at High Risk of Exposure to the Monkeypox Virus
  • COVID-19 Update for Virginia – July 22
    • EVUSHELD Dosing Schedule Change
    • Paxlovid – Pharmacist Prescriptive Authority
    • CDC Recommends Novavax COVID-19 Vaccine for Individuals Aged 18 Years and Older
    • Monkeypox Updates
    • CDC Health Alert Network: Recent Reports of Human Parechovirus (PeV) in the U.S.
  • COVID-19 Update for Virginia – June 24
    • CDC Recommends COVID-19 Vaccines for Children Aged 6 Months to 5 Years
    • Pfizer-BioNTech (Pfizer) COVID-19 Vaccine
    • Moderna COVID-19 Vaccine
    • Additional information about the use of Pfizer and Moderna vaccines in young children
    • CDC Recommends Moderna COVID-19 Vaccine for Children Aged 6 Through 17 Years
    • Monkeypox Outbreak Update
  • Monkeypox Update for Virginia – June 14
  • COVID-19 Update for Virginia – May 20
    • Infant Formula Shortage
    • COVID-19
    • Monkeypox
    • Expected arrival of Ukrainian Refugees
  • Acute Hepatitis with Unknown Etiology in Children – April 22
  • COVID-19 Update for Virginia – April 5
    • Second COVID-19 mRNA Vaccine Booster Doses
    • COVID-19 Lab Reporting Updates
    • HRSA Ending Reimbursement for COVID-19 Testing, Vaccines, and Therapeutics
    • Possible FDA Deauthorization of Sotrovimab in Virginia
  • COVID-19 Update for Virginia – March 10
    • CDC COVID-19 Community Levels
    • COVID-19 Therapeutics Update
    • Consideration of Increased Interval Between 1st and 2nd Doses of mRNA Vaccines
    • Prioritization of COVID-19 Antigen Testing Supplies
    • List of Medical Conditions that Put People at Higher Risk for Severe COVID-19
  • COVID-19 Update for Virginia – February 17
    • CDC Updates Vaccine Recommendations for Immunocompromised Individuals and Those Who Received Passive Antibody Products
    • FDA Grants Emergency Use Authorization to Bebtelovimab
    • New Isolation and Quarantine Calculators
    • National Blood Shortage
  • COVID-19 Update for Virginia – February 10
    • State Health Commissioner Issues Interim Guidelines for the Prioritization of the Use of Rapid COVID-19 Tests
    • CDC Recommends FDA-Approved Moderna COVID-19 Vaccine
    • Therapeutics Updates
    • CDC and CMS Updates for Infection Prevention in Healthcare Settings
    • Keeping Up With COVID Video Series
  • COVID-19 Update for Virginia – January 11
    • New Declaration of Limited State of Emergency in Virginia and Executive Order 84
    • Updated Recommendations for COVID-19 Vaccines and Staying Up to Date
    • Update on Omicron Surge and Therapeutics
    • CDC Shortens Isolation and Quarantine Periods

2021

  • COVID-19 Update for Virginia – December 29
    • Updated and Shortened Isolation and Quarantine Guidance for the General Population
    • Updated Guidance for the Management of Healthcare Personnel with SARS-CoV-2 Infection or Exposure
    • Therapeutics Update
  • COVID-19 Update for Virginia – December 20
    • CDC Prefers mRNA Vaccines Over the Johnson & Johnson COVID-19 Vaccine
    • Providers Required to Report All Immunizations to Virginia Immunization Information System Starting January 2022
  • COVID-19 Update for Virginia – December 14
    • Omicron (B.1.1.529) Variant Detected in Virginia
    • COVID-19 Booster Doses Recommended for Everyone Aged 16 Years and Older
    • COVID-19 Therapeutics Update
    • Widespread Flu Activity in Virginia
  • COVID-19 Update for Virginia – December 3
    • Update on the Omicron Variant – Clarification added Dec. 7, 2021
    • CDC’s Health Alert Network (HAN) Health Advisory About Increasing Seasonal Influenza A (H3N2)
    • Upcoming Webinars on Monoclonal Antibodies and COVID-19 Vaccines
  • COVID-19 Update for Virginia – November 22
    • FDA and CDC Expand Eligibility for COVID-19 Booster Doses to All Adults
    • CDC Updates Vaccine Guidance People Who Received COVID-19 Vaccine Outside the U.S. and People Who Received COVID-19 Vaccine as Part of a Clinical Trial
    • Vaccine Administration Errors with Pediatric COVID-19 Vaccine
    • VDH Releases New Monoclonal Antibody Locator Tool and Provides Additional Updates
  • COVID-19 Update for Virginia – November 5
    • Pfizer-BioNTech COVID-19 Vaccine Authorized and Recommended for 5–11 Year Olds
  • COVID-19 Update for Virginia – October 28
    • CDC Expands Eligibility for COVID-19 Booster Doses for Certain Recipients of Moderna and Johnson & Johnson COVID-19 Vaccines and Allows for Heterologous Booster Doses
    • Update on Pfizer COVID-19 Vaccines for Children Aged 5 to 11 Years
    • VDH Webinar on Understanding COVID-19 Vaccine: What the Evidence Tells Us
    • VDH Statement on the Use of Ivermectin for the Prevention or Treatment of COVID-19
  • COVID-19 Update for Virginia – September 30
    • CDC Recommends a Booster Dose of Pfizer-BioNTech Vaccine Following a Primary Series for Certain Populations
    • COVID-19 Vaccination and Pregnancy
    • Vaccination for Children Aged 5 to 11 Years
    • Update on Monoclonal Antibody Treatment for COVID-19 Distribution
  • COVID-19 Updates for Virginia – September 20
    • Back-to-School Resources and Reminders
    • CDC’s Health Alert Network (HAN) Health Advisory about Ivermectin
    • Update on Monoclonal Antibody Treatment for COVID-19
    • Virginia Immunization Information System Requires All Immunizations January 2022
  • Update on Measles in Virginia – September 14
  • COVID-19 Update for Virginia – August 26
    • FDA Grants Full Approval to Pfizer-BioNTech COVID-19 Vaccine
    • Booster Dose of mRNA Vaccine for General Adult Population to Start in Mid-September
    • Coadministration of COVID-19 and Influenza Vaccines
    • Additional Updates about Respiratory Syncytial Virus
  • COVID-19 Update for Virginia – August 16
    • CDC Recommends an Additional Dose of mRNA Vaccine Following a Primary Series in Certain Immunocompromised People
    • CDC Strengthens Vaccine Recommendation for People Who Are Pregnant, Breastfeeding, or Thinking of Becoming Pregnant
    • VDH Reminds Clinicians of Testing and Masking Recommendations
  • Health Commissioner Update – August 6
    • Updates on the Delta (B.1.617.2) Variant and Guidance
    • Monoclonal Antibody Therapy and Postexposure Prophylaxis
    • Guillain-Barré syndrome after receiving Johnson & Johnson’s COVID-19 vaccine
    • Updates about Non-COVID-19 Respiratory Viruses
    • Burkholderia cepacia complex Infections Associated with Contaminated Ultrasound Gel
    • Back-to-school Vaccinations and Updated Resources
  • COVID-19 Update for Virginia – June 30
    • Myocarditis and Pericarditis Following mRNA COVID-19 Vaccination
    • Monoclonal Antibody Update
    • Updates on the Delta (B.1.617.2) and the Epsilon (B.1.427/B.1.429) Variants
    • New CDC Viral Testing Tool
    • Preparing for Heat-Related Illness
  • COVID-19 Update for Virginia – May 14
    • Updated CDC Guidance for Fully Vaccinated People
    • Pfizer-BioNTech COVID-19 Authorized and Recommended for 12-15 Year Olds
    • Importance of Not Missing COVID-19 Vaccination Opportunities
    • Importance of Second Dose Administration of Pfizer-BioNTech and Moderna Vaccines
    • Upcoming Webinar with a Pediatric COVID-19 Vaccination Expert Panel
    • Importance of Testing Returning International Travelers and Encouraging Quarantine
  • Candida auris Cases are on the Rise in Virginia – May 7
  • COVID-19 Update for Virginia – April 7
    • Importance of Diagnostic and Screening COVID-19 Testing in Virginia
    • SARS-CoV-2 Variants
    • Importance of Reporting COVID-19 Outbreaks
    • Cases of Vaccine Breakthrough
  • COVID-19 Update for Virginia – March 4
    • Johnson & Johnson’s Janssen COVID-19 Vaccine
    • Patient Outreach about COVID-19 Vaccination
    • COVID-19 Vaccination Clinic Best Practices
    • Updated Quarantine Recommendations for Fully Vaccinated People
    • Work Restrictions for Exposed Healthcare Personnel
    • Multisystem Inflammatory Syndrome in Children (MIS-C)
    • SARS-CoV-2 Variants in Virginia
    • Ebola Virus Disease Outbreaks in the Democratic Republic of Congo and Guinea
  • COVID-19 Update for Virginia – January 25
    • Required Information for COVID-19 Immunizations
    • COVID-19 Vaccine Allocation Methodology
    • B.1.1.7 Variant of COVID-19 Virus Detected in Virginia
    • Travel Restrictions for People Entering the United States
    • New Text Messaging Service to Streamline Positive Test Result Awareness and Exposure Notifications
  • COVID-19 Update for Virginia – January 11
    • Updates on COVID-19 Vaccine Prioritization for Phases 1b and 1c
    • Submit your intent today to administer COVID-19 vaccine
    • Enroll today to become a vaccination provider in Virginia’s Medical Reserve Corps
    • FDA Communication: Genetic Variants of SARS-CoV-2 May Lead to False Negative Results with Molecular Tests for Detection of SARS-CoV-2
    • FDA Safety Communication: Risk of False Results with the Curative SARS-CoV-2 Test for COVID-19

2020

2019